Lonza Celebrates the 30th Anniversary of Clonetics™ Products, the Pioneer of Primary Cells

Clonetics Corporation was founded in 1984 as the pioneer in the human primary cell culture business. The company was the first to develop a novel technology that allowed culturing of primary human cells outside of their tissue origin. This was a crucial step forward in the research community as scientists then had the capacity to study tissue-specific characteristics on a cellular level in vitro and to develop more biologically relevant models. Recognizing the importance of this technology, the company was also well funded with many Small Business Innovation Research (SBIR) grants in its early years². After its inception, Clonetics Corporation went through acquisitions that further strengthened the portfolio and its commercial reach in the cell culture market. Today, the Clonetics™ brand is offered by Lonza Walkersville, Inc. and Lonza Cologne GmbH and maintains the leading position in the primary cells market. 

Clonetics Corporation first led its primary cell business with select normal cell types supporting dermal, vascular and airway research. Over time, this product line has grown to more than 100+ cell types spanning numerous research areas. Aside from the sheer quantity, the portfolio quality has also expanded to include normal as well as diseased cells from asthma, COPD, diabetes and cystic fibrosis tissue. For each cell type, careful consideration is given to maintain broad donor variety, highest quality control, batch-to-batch consistency, and large-scale production capacity. 

Currently, the Clonetics™ brand represents the largest primary cell and media selection on the market. It is well recognized for its outstanding scientific support team and its dedication to consistent, high-performing products.